The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Rational design of inhibitors that bind to inactive kinase conformations
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Crystal structure of the tyrosine kinase domain of the human insulin receptor
Hubbard, S. R., Wei, L., & Hendrickson, W. A. (1994) · Nature · doi:10.1038/372746a0 · Cited by 1,080
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Self-citationStructural basis of inhibitor selectivity in MAP kinases
Wang, Z., Canagarajah, B. J., Boehm, J. C., Kassisà, S., Cobb, M. H., Young, P. R., Abdel-Meguid, S., Adams, J. L., & Goldsmith, E. J. (1998) · Structure · doi:10.1016/s0969-2126(98)00113-0 · Cited by 423
Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors
Traxler, P., & Furet, P. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00044-8 · Cited by 388
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Regan, J., Breitfelder, S., Cirillo, P., Gilmore, T., Graham, A. G., Hickey, E., Klaus, B., Madwed, J., Moriak, M., Moss, N., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020057r · Cited by 348
The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
Wilson, K. P., McCaffrey, P. G., Hsiao, K., Pazhanisamy, S., Galullo, V., Bemis, G. W., Fitzgibbon, M. J., Caron, P. R., Murcko, M. A., & Su, M. S. S. (1997) · Chemistry & Biology · doi:10.1016/s1074-5521(97)90194-0 · Cited by 274
Imatinib: a selective tyrosine kinase inhibitor
Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T., & Zimmermann, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80599-8 · Cited by 265
Structural basis for selective inhibition of Src family kinases by PP1
Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D. O., & Shokat, K. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80118-5 · Cited by 252
Self-citationShewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., & Kuyper, L. F. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990401t · Cited by 233
A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase
Atwell, S., Adams, J. M., Badger, J., Buchanan, M. D., Feil, I. K., Froning, K. J., Gao, X., Hendle, J., Keegan, K., Leon, B. C., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409792200 · Cited by 193
Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation
Gill, A. L., Frederickson, M., Cleasby, A., Woodhead, S. J., Carr, M. G., Woodhead, A. J., Walker, M. T., Congreve, M. S., Devine, L. A., Tisi, D., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049575n · Cited by 186
Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors
Dai, Y., Guo, Y. P., Frey, R. R., Ji, Z., Curtin, M. L., Ahmed, A. A., Albert, D. H., Arnold, L. D., Arries, S. S., Barlozzari, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050458h · Cited by 163
Kubo, K., Shimizu, T., Ohyama, S.-I., Murooka, H., Iwai, A., Nakamura, K., Hasegawa, K., Kobayashi, Y., Takahashi, N. K., Takahashi, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm030427r · Cited by 150
Design and Discovery of Small Molecules Targeting Raf-1 Kinase
Lowinger, T. B., Riedl, B., Dumas, J., & Smith, R. A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393125 · Cited by 150
Manley, P. W., Bold, G., Brüggen, J., Fendrich, G., Furet, P., Mestan, J., Schnell, C., Stolz, B., Meyer, T., Meyhack, B., et al. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.010 · Cited by 136
Heron, N. M., Anderson, M., Blowers, D. P., Breed, J., Eden, J. M., Green, S., Hill, G. B., Johnson, T., Jung, F. H., McMiken, H. H. J., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.11.053 · Cited by 128
The role of tyrosine phosphorylation in cell growth and disease.
Hunter, T. R. (1998) · PubMed · Cited by 91
Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
Mol, C. D., Fabbro, D., & Hosfield, D. J. (2004) · PubMed · Cited by 67
Second-generation kinase inhibitors
Klebl, B., & Müller, G. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.975 · Cited by 59
Exploiting structural principles to design cyclin-dependent kinase inhibitors
Noble, M. E. M., Barrett, P. J., Endicott, J., Johnson, L., McDonnell, J., Robertson, G., & Zawaira, A. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.019 · Cited by 31
(2002) · PubMed
Cited by
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Self-citationComprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Metadata
- Authors
- Liu, Y., & Gray, N. S.
- Venue
- Nature Chemical Biology
- Published
- 2006-06-16
- Volume
- 2
- Issue
- 7
- Pages
- 358-364
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2079398727
- Cited by
- 1,094
- References
- 28
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.